Drug intelligence / Profile preview

Albunique

Development stage: Preclinical
Lead developer: Albutec
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Albunique is an enhanced albumin solution developed by Albutec GmbH, featuring proprietary detoxification technology (Hepalbin adsorbent). It is designed for intravenous use, focusing on improving albumin binding capacity for use in extracorporeal albumin dialysis (ECAD) and advanced liver support therapies. The technology aims to support liver and multi-organ detoxification in conditions such as acute or chronic liver failure, bridging patients to transplantation or recovery by facilitating the removal of protein-bound and water-soluble toxins. Unlike conventional albumin products, Albunique incorporates advanced sorbent technology for higher detoxification efficiency.

Brand names: Albunique
Other names: ALBUNIQUE

Beyond the preview

Go deeper on Albunique.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albunique.

Explore the full profile